Current Applications for Overcoming Resistance to Targeted Therapies

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Resistance to Targeted Anti-Cancer Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/978-3-030-21477-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

  2018cited by this paper
• Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells

  2018influential reference
• Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells

  2018influential reference
• Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.

  2018influential reference
• Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

  2018cited by this paper
• Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance

  2018cited by this paper
• Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo

  2018influential reference
• Folate‐targeted liposomal nitrooxy‐doxorubicin: An effective tool against P‐glycoprotein‐positive and folate receptor‐positive tumors

  2018cited by this paper
• Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

  2018influential reference
• Aberrant RNA Splicing in Cancer and Drug Resistance

  2018cited by this paper
• Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo

  2018cited by this paper
• Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells

  2018influential reference
• Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer

  2018influential reference
• Capsaicin and Piperine Can Overcome Multidrug Resistance in Cancer Cells to Doxorubicin

  2018cited by this paper
• Novel CD44-downstream signaling pathways mediating breast tumor invasion

  2018cited by this paper
• Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

  2018influential reference
• Effects of increased accumulation of doxorubicin due to emodin on efflux transporter and LRP1 expression in lung adenocarcinoma and colorectal carcinoma cells

  2018cited by this paper
• Photoresponsive Nanovehicle for Two Independent Wavelength Light-Triggered Sequential Release of P-gp shRNA and Doxorubicin To Optimize and Enhance Synergistic Therapy of Multidrug-Resistant Cancer.

  2018influential reference
• Ribociclib shows potential for pharmacokinetic drug‐drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro

  2018influential reference
• Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells

  2018influential reference
• Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

  2018influential reference
• Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

  2018cited by this paper
• Scutellaria baicalensis targets the hypoxia‐inducible factor‐1α and enhances cisplatin efficacy in ovarian cancer

  2018cited by this paper
• The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

  2018influential reference
• Inhibition effects of acridone on the growth of breast cancer cells in vivo.

  2018influential reference
• Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)

  2018cited by this paper
• Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

  2017cited by this paper
• Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

  2017influential reference
• Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles

  2017cited by this paper
• Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

  2017influential reference
• A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance

  2017influential reference
• The combination of checkpoint immunotherapy and targeted therapy in cancer.

  2017cited by this paper
• ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance

  2017influential reference
• Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1α

  2017influential reference
• Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma

  2017cited by this paper
• GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

  2017influential reference
• Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer

  2017cited by this paper
• Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ABC transporter ABCG2

  2017cited by this paper
• The challenge of targeting cancer stem cells to halt metastasis.

  2017influential reference
• HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers

  2017cited by this paper
• Stimulus-Responsive Short Peptide Nanogels for Controlled Intracellular Drug Release and for Overcoming Tumor Resistance.

  2017cited by this paper
• GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand

  2017cited by this paper
• Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.

  2017influential reference
• Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells

  2017cited by this paper
• Prospects for combining targeted and conventional cancer therapy with immunotherapy

  2017cited by this paper
• Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

  2017cited by this paper
• Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma

  2017cited by this paper
• Targeted multidrug delivery system to overcome chemoresistance in breast cancer

  2017influential reference
• The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

  2017cited by this paper
• EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.

  2016influential reference
• Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

  2016cited by this paper
• Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.

  2016cited by this paper
• Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

  2016cited by this paper
• Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

  2016cited by this paper
• Actively Targeted Nanoparticles for Drug Delivery to Tumor.

  2016influential reference
• A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma

  2016cited by this paper
• Multi-functionalized hyaluronic acid nanogels crosslinked with carbon dots as dual receptor-mediated targeting tumor theranostics.

  2016influential reference
• Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.

  2016cited by this paper
• MMP2-Sensitive PEG-Lipid Copolymers: A New Type of Tumor-Targeted P-Glycoprotein Inhibitor.

  2016cited by this paper
• Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway

  2016cited by this paper
• Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo

  2016influential reference
• Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016cited by this paper
• Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

  2015cited by this paper
• Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.

  2015cited by this paper
• The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

  2015cited by this paper
• Soluplus(®) micelles as a potential drug delivery system for reversal of resistant tumor.

  2015cited by this paper
• Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance

  2015influential reference
• Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer.

  2015influential reference
• Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells.

  2015cited by this paper
• New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies

  2015cited by this paper
• GDF15 promotes EMT and metastasis in colorectal cancer

  2015cited by this paper
• Overcoming Resistance to Targeted Therapies in Cancer.

  2015cited by this paper
• Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1

  2015influential reference
• Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.

  2015cited by this paper
• Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

  2015influential reference
• Pelitinib (EKB‐569) targets the up‐regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer

  2015cited by this paper
• Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma

  2015cited by this paper
• PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy

  2015influential reference
• Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.

  2015cited by this paper
• Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.

  2015influential reference
• Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles.

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.

  2015influential reference
• Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones.

  2015influential reference
• Sunitinib resistance in renal cell carcinoma

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo

  2014influential reference
• The accelerated approval of oncologic drugs: lessons from ponatinib.

  2014influential reference
• Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting

  2014influential reference
• Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer.

  2014influential reference
• Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters

  2014influential reference
• Tumour heterogeneity and the evolution of polyclonal drug resistance

  2014influential reference
• Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells

  2014influential reference
• Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population

  2014influential reference
• β-Elemene Reverses Chemoresistance of Breast Cancer via Regulating MDR-Related MicroRNA Expression

  2014influential reference
• Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper

• Cannabinoids Transmogrify Cancer Metabolic Phenotype via Epigenetic Reprogramming and a Novel CBD Biased G Protein-Coupled Receptor Signaling Platform

  2023cites this paper
• A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities

  2023cites this paper
• Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression

  2022cites this paper
• Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases

  2022cites this paper
• Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles

  2021cites this paper